A ground-breaking treatment for cancer described by doctors as being like a ‘heat seeking missile’ has boosted survival rates and quality of life for patients with fewer side effects.

Artera and Tempus are collaborating to expand access to Artera’s AI-based prostate cancer test. Currently connected to more ...

Nubeqa plus ADT improved rPFS in mHSPC regardless of disease volume, reducing the risk of radiological progression or death ...

The primary endpoint is objective response rate, with progression-free survival a key secondary endpoint. The study includes a pre-registration step for arm determination by the molecular tumor board.

Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to prostate cancer poster session. Dr. Zachary Klaassen presented the results of a population-based analysis evaluating ...

Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic ...

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate ...

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is ...

Prostate cancer is the leading cancer type in men. Getting screened can help you catch cancer early, when it’s easier to ...

In the next in our series, GP Dr Roger Henderson debunks common myths about prostate cancer – and highlights some less ...

Accra, Feb 13, GNA – Ghana lost 17,944 persons to cancer in 2022, recording an estimated 27, 385 new cancer cases in that year, the Ghana Health Service (GHS) has said.

Testosterone therapy after prostate cancer surgery does not appear to increase biochemical recurrence (BCR) risk in patients with low-risk disease, investigators report.